Skip to content
DraconiticResearch
Search Sources API
186,541 studies31 sourcesUpdated 42 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

454 Second primary hematologic malignancies in melanoma survivors before and after the introduction of immune checkpoint inhibitors: a population-based SEER analysis

  • Jeffrey Afrifa-Yamoah1
  • Damilola Ologbe1
  • Duresha Malik2
  • Michael Asare3
  • Josephine Poku-Adusei4
  • Olanipekun Lanny Ntukidem2
  • Stanley Emmanuel Atencah5
  • Ayodeji Johnson6
6 affiliations
  1. 1Trinity Health Ann Arbor Hospital, Ann Arbor, MI, USA
  2. 2Trinity Health Ann Arbor, Ann Arbor, MI, USA
  3. 3BronxCare Health System, Bronx, NY, USA
  4. 4Haywood Regional Medical Center, Clyde, NC, USA
  5. 5Piedmont Athens Regional Medical Center, Athens, GA, USA
  6. 6Boston Medical Centre, Boston, MA, USA
Open at sourceDOICite

Related

  1. Myeloid-derived suppressor cells in hematologic malignancies: A current state of the field
    Yulia Nefedova, Dmitry I Gabrilovich
    The Journal of Immunology Author ChoicePeer-reviewedPublisher termsFull textImmunologyPMC
  2. Central Nervous System Toxoplasmosis Beyond HIV in Patients with Hematologic Malignancies: A Contemporary Narrative Review and Illustrative Case Synthesis
    Aleksandra Łanocha, Oliwia Pawelec-Pęciak, Karolina Kot +3
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textMicrobiologyCrossrefEurope PMC
  3. Intelligent immunotherapy: AI-driven optimization of CAR-T therapy in hematologic malignancies
    Farshid Farhadzadeh, Amirhossien Borji, Cena Aram +3
    iSciencePeer-reviewedCC BY-NC-ND 4.0Full textImmunologyCell PressCrossrefEurope PMC
  4. Electronic Genome Mapping Enables High-Resolution Cytogenomic Profiling of Hematologic Malignancies: A Proof-of-Principle Study
    A. K. Mondal, V. VASHISHT, Y. ZHANG +6
    medRxivPreprintCC BYFull textGenetics & genomicsmedRxiv
  5. Commentary: Hemophagocytic lymphohistiocytosis induced by immune checkpoint inhibitors: observations and proposed clinical management
    Gauthier Coussement, Maxime Ilzkovitz, Loïc Baudelet +2
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyGeneral medicineCrossrefDOAJ

Cite

BibTeXRIS
BibTeX
@article{afrifayamoah2026second,
  title = {{454 Second primary hematologic malignancies in melanoma survivors before and after the introduction of immune checkpoint inhibitors: a population-based SEER analysis}},
  author = {Jeffrey Afrifa-Yamoah and Damilola Ologbe and Duresha Malik and Michael Asare and Josephine Poku-Adusei and Olanipekun Lanny Ntukidem and Stanley Emmanuel Atencah and Ayodeji Johnson},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0454},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0454},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 454 Second primary hematologic malignancies in melanoma survivors before and after the introduction of immune checkpoint inhibitors: a population-based SEER analysis
AU  - Jeffrey Afrifa-Yamoah
AU  - Damilola Ologbe
AU  - Duresha Malik
AU  - Michael Asare
AU  - Josephine Poku-Adusei
AU  - Olanipekun Lanny Ntukidem
AU  - Stanley Emmanuel Atencah
AU  - Ayodeji Johnson
PY  - 2026
DA  - 2026/11/04
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0454
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0454
SN  - 2051-1426
ER  -